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Abstract
The capacity of T cells to bind peptide/MHC ligands changes with T cell development and
differentiation. Here we study changes in peptide/MHC multimer binding following T cell activation.
Surprisingly, T cell activation caused a marked reduction in specific peptide/MHC Class I multimer
binding, which was distinct from transient TCR down-regulation, and was especially dramatic for
engagement with low-affinity peptide/MHC ligands. Direct CD8–Class I interactions were also
profoundly and rapidly impaired following T cell stimulation, even though surface CD8a and CD8b
levels were unchanged after activation, suggesting that decreased CD8 co-receptor binding
contributes to this effect. Finally, we show that enzymatic desialylation restores much of the multimer
binding on activated T cells, suggesting that altered glycosylation may inhibit TCR/CD8 binding to
peptide/MHC ligands. These radical changes in activated T cells’ ability to perceive peptide/MHC
ligands may contribute to selective outgrowth of clones with high affinity for the stimulatory ligand.
Introduction
Activation is thought to enhance the reactivity and sensitivity
of T lymphocytes for their cognate peptide/MHC ligands.
Various reports have suggested that, compared with naive
cells, antigen-experienced effector andmemory Tcells require
lower doses of their specific antigen/MHC ligand for activation,
respond more quickly to these stimuli and/or have greater
flexibility in detecting lower affinity variants of the antigenic
ligand (1–4). Indeed, it has been estimated that CTL lysis can
be provoked by engagement of 1–3 peptide/MHC ligands
(5, 6). In one study on CD8 Tcells, effector cells were superior
to naive T cells in their capacity to aggregate dimeric
peptide/MHC ligands, an effect which appeared to correlate
with changes in lipid raft content or distribution (7), perhaps
providing a mechanism to explain heightened sensitivity of
these cells. In addition, TCR stimulation on CTL clones leads
to enhanced CD8 binding to Class I MHC molecules directly,
in the absence of TCR recognition of the peptide–MHC
complex (also called ‘non-cognate’ CD8 binding) (8, 9). We
and others demonstrated that immature thymocytes are more
efficient than mature T cells at binding non-cognate Class I
MHC molecules, a property which appears to correlate with
lower levels of cell-surface sialylation on immature T cells
(10, 11). Interestingly, the fact that activated T cells also have
lowered levels of surface sialylation (12–16) might suggest
that they too would be enhanced for non-cognate CD8
binding.
On the other hand, some groups have reported that
stimulation of T cells reduces their ability to bind specific
peptide/MHC multimers. While in some cases, a reduction in
multimer binding might simply be a consequence of the
well-known phenomenon of TCR down-regulation following
T cell activation (3, 17), this appears not to explain the loss
of multimer binding in several studies (18–20). In one elegant
series of studies, activated T cells specific for sub-dominant
influenza epitopes were shown to be unable to bind specific
peptide/MHC multimers, although TCR and CD8 expression
levels were found to be normal (21, 22). Furthermore, reduced
multimer binding could be induced by disruption of lipid raft
domains even though TCR and CD8 levels were maintained
(22), indicating that multimer binding can be compromised
despite sustained surface expression of TCR and CD8.
Therefore, it is currently unclear whether T cell activation
leads to enhanced or diminished peptide/MHC ligand binding,
with reports supporting both conclusions.
We previously used peptide/MHC Class I multimers to
explore the requirement for CD8 in binding to cognate TCR
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ligands on naive T cells (23), and also to study the de-
velopmental regulation of CD8 non-cognate binding (10).
These and other studies suggested that there is considerable
variability in multimer staining depending on the maturation
state of the T cell and the participation of the CD8ab co-
receptor (10, 11, 24, 25). In this report, we studied the
changes in peptide/MHC multimer binding which accompany
T cell activation. We make the surprising finding that the
capacity of activated CD8 Tcells to bind cognate multimers is
severely depressed for several days following stimulation,
even after TCR expression has returned to normal levels. We
find that the loss of cognate binding is more dramatic and
sustained when low-affinity TCR ligands are studied, suggest-
ing that activated CD8 Tcells may preferentially lose sensitivity
to weak agonists. These changes in tetramer binding are in
part due to alterations in CD8–Class I binding, since we ob-
serve a precipitous decline in non-cognate multimer binding
with T cell stimulation, despite the fact that CD8a and CD8b
expression levels are maintained after T cell activation. Thus,
our data suggest that CD8 T cell activation induces a state of
impaired engagement with Class I MHC–peptide complexes,




C57BL/6 mice were obtained from Jackson Laboratory (Bar
Harbor, ME, USA). OT-I and 2C mice were generated and
maintained under specific pathogen-free conditions. Major
lymph nodes and/or spleens were harvested, and single-cell
suspensions were created by mashing over a metal mesh
screen immersed in HBSS (GIBCO), filtered and then
centrifuged and re-suspended in ‘RP10’ medium (RPMI 1640
from GIBCO containing 10% FCS plus 5 mM HEPES, 50 U
penicillin, 50 lg ml1 streptomycin and 50 lg ml1 gentamicin
sulfate, 50 lM 2-mercaptoethanol and 2 mM glutamine). Cells
were used for subsequent experiments and cultures without
further purification.
Peptides and MHC multimers
The peptides ovalbumin peptide (OVA) (SIINFEKL), G4
(SIIGFEKL), SIY (SIYRYYGL), SIY-A6 (SIYRYAGL), VP10
(STLNFNNL) and P815p (HIYEFPQL) were synthesized by
Research Genetics or Invitrogen. Kb–b2m–peptide complexes
were made as described previously (23) from procedures
adapted from Busch and Altman (26, 27). Biotinylated
monomers were concentrated to 1 mg ml1 and stored in
10–100 ll aliquots at 80C. Multimers were prepared by
mixing with regular grade streptavidin–phycoerythrin (SA–PE)
conjugate (Molecular Probes, Eugene, OR, USA) at an 8:1
molar ratio (1:1 mass ratio) and incubating at room tempera-
ture for 30–60 min prior to staining. The mass concentration
of multimers was assumed to be ~23 the mass concentration
of SA–PE (e.g. 0.5 mg ml1 of SA–PE yields ~1 mg ml1
multimers). Multimers were used at 2–50 lg ml1 without
further purification. We found that multimer staining intensity,
especially with low-affinity peptide/MHC ligands, decreased
with prolonged storage of pre-formed multimers. Hence for
optimal sensitivity, non-cognate and low-affinity multimer bind-
ing assays were performed within 1–2 h after multimerization.
Antibodies, multimer staining and flow cytometry
T cells (0.5 3 106 to 1 3 106) were stained on ice with
multimers in 100 ll of FACS buffer (PBS, 1% FCS and
0.2% sodium azide) for 30 min (FACS buffer conditions) or
RP10 for 2 h (RP10 conditions). Standard staining conditions
include multimers at 10 lg ml1 (23), which gives staining
close to saturating levels (data not shown), but higher or lower
concentrations were used in some experiments, as indicated.
Staining at 4C was used to enhance the low-affinity
interactions studied, since preliminary experiments suggested
that staining at 37C decreased low-affinity multimer binding,
similar to the observations of Whelan et al. (28), and also
raised background, non-CD8 binding (data not shown). In
some experiments, CD8 dependence for multimer binding
was tested by inclusion of the blocking anti-CD8a antibody,
CT-CD8a (Caltag Laboratories), which was used at 5 lg ml1
of FITC-conjugated antibody added immediately prior to the
multimer. For all other multimer stains, we gated on CD8+ cells
in flow cytometric analyses by using the anti-CD8a anti-
body, 53-6.7 (5 lg ml1, FITC conjugated) (PharMingen or
Biolegend). The 53-6.7 is known to enhance Class I MHC
multimer binding (23), but it does not influence prebound
multimers (data not shown). Therefore, with the exception of
Fig. 6 (as indicated), cells were stained first with multimers and
then washed and stained with 53-6.7. All surface staining
aside from the multimer stains were done for 30 min on ice in
PBS + 10% FCS. Anti-CD8b (53-5.8), anti-Va2 (B20.1) and
anti-Vb8 (F23.1) antibodies were purchased from PharMingen
or Biolegend and used at 1–2 lg ml1. Peanut agglutinin
(PNA)–FITC was purchased from Vector Laboratories and
used at 0.5 lg ml1. Cells were analyzed on a Becton
Dickinson FACSCaliburTM or LSRII, and data were analyzed
using FlowJo (TreeStar, San Carlos, CA, USA) software.
In vitro T cell stimulation
Unpurified OT-I lymph node cells (8 3 105) and 2 3 105
C57BL/6 (H-2b) unpurified splenocytes in 200 ll RP10
containing the indicated doses of OVA were added to 96-
well flat-bottom tissue culture treated wells and spun down
briefly (300–4003 g, 1 min). For Figs 3 and 4, OT-I or 2C lymph
node Tcells (253 106) and 53 106 C57BL/6 splenocytes were
cultured in 10 ml RP10 in petri dishes (100 mm diameter) with
10 nM OVA (for OT-I cells) or 1 lM SIY peptide (for 2C cells).
Cell cultures were maintained in 37C incubators under 5%
CO2 tension for the times indicated. Media were changed daily
starting at 2–3 days post-stimulation and IL-2 (10 ng ml1;
Biosource) was added at the same time. Cultures were split as
necessary from day 2 of activation.
TCR blockade of multimer staining
Naive OT-I T cells (0.5 3 106 to 1 3 106) were incubated
with the Va2-specific blocking antibody (B20.1) at various
doses (78 ng ml1–5 lg ml1) in 100 ll of RP10 for 30 min at
4C. Cells were washed with RP10 and stained with 1 lg ml1
PE-conjugated B20.1 (PharMingen or Biolegend) for 30 min
at 4C in RP10 to detect remaining levels of unbound TCR.
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In parallel, naive or activated OT-I cells were stained with
OVA/Kb multimers (2 lg ml1), and binding was measured by
flow cytometry as described above.
Neuraminidase treatment
Cells were treated with neuraminidase as previously de-
scribed (10). Briefly, cells were prepared as above, washed
one to two times in HBSS and re-suspended at 1 3 106 to
2 3 106 ml1 in HBSS. Following pre-incubation at 37C for
~15 min, neuraminidase (0.0095 units per 1–2 million cells)
from Vibrio cholerae (Sigma, St Louis, MO, USA) was added,
and the treated cells were incubated at 37C for 20–40 min.
Cells were washed one to two times with RP10 before staining
with the indicated multimers. Controls were processed in the
same way without addition of neuraminidase.
Results
Specific peptide/MHC binding to OT-I CD8+ T cells is
impaired following activation, despite high levels of
surface TCR
We wished to investigate how T cell activation influenced
peptide/MHC binding. Class I MHC-restricted OT-I TCR trans-
genic T cells were activated in vitro, and then assessed for
their ability to bind specific Class I MHCmultimers. Within 24-h
post-activation, we observed a dramatic loss in OT-I binding to
the multimeric Class I MHC ligand, OVA/Kb (Fig. 1A). The loss
in multimer binding at this time point might be explained by the
well-documented phenomenon of TCR down-regulation that
accompany Tcell activation (17, 29, 30) (Fig. 1A). However, we
were surprised to observe that OVA/Kb binding was still
impaired at days 3 and 4 after activation, despite the fact that
surface TCR expression had returned to the levels seen on
naive OT-I cells (Fig. 1A). In addition, we studied binding of
multimers loaded with G4 peptide, a variant of OVA that has
lower affinity for the OT-I TCR (31). Binding of G4/Kb multimers
(even when offered at high dose) was even more severely
impaired than binding of the higher affinity OVA/Kb ligand
(Fig. 1A). Moreover, loss of G4/Kb binding was sustained
through days 4–5 of activation, while binding of OVA/Kb was
substantially restored at these time points (Fig. 1A and data
not shown). These findings were observed over a range of
multimer doses. As shown in Fig. 1(B), titration of both OVA/Kb
and G4/Kb multimers showed a consistent result in that
specific multimer binding to activated OT-I cells was severely
reduced compared with unstimulated OT-I cells.
The above experiments suggested that T cell activation
caused a disproportionate loss in Class I antigen binding
that could not be explained by TCR down-regulation since
the percent loss in multimer binding exceeded the percent
loss in TCR expression levels and multimer binding was still
impaired following recovery of surface TCR levels (Fig. 1).
However, since TCR affinities for specific peptide/MHC li-
gands are low, efficient multimer binding is expected to be
highly sensitive to the density of surface TCR. Thus, it was
possible that a slight decrease in TCR levels would cause
a disproportionate loss in multimer binding.
We tested this idea by performing a TCR blockade ex-
periment to mimic TCR down-regulation. Naive OT-I cells were
coated with increasing doses of a blocking TCR antibody
(B20.1) to progressively inhibit the capacity of surface OT-I
TCRs from binding multimers. The amount of remaining
available TCR was then quantitated by measuring the level
of staining with the PE-labeled B20.1 antibody. Alternatively,
the antibody-coated naive OT-I cells were stained with OVA/Kb
multimers. This allowed us to determine a relationship be-
tween available surface TCR and multimer binding, as shown
in Fig. 2(A). Blockade with the B20 antibody led to efficient
blockade of the OT-I TCR and, at high doses, resulted in loss
of >99% of OVA/Kb multimer binding to naive OT-I cells
(Fig. 2A). Next, we compared multimer staining on activated
OT-I cells (which were not treated with anti-TCR antibody) in
comparison with naive OT-I cells subjected to TCR blockade.
We observed that, even at equivalent levels of accessible
TCRs, the multimer binding on activated OT-I cells was lower
than that on naive Tcells (Fig. 2B). For example, activation with
1 nM OVA resulted in loss of ~50% of surface TCR by day 1,
yet cognate multimer staining was reduced by ~98% (Figs 2B
and C). We note some variation between experiments in the
magnitude of the TCR down-regulation and loss of multimer
binding, especially in cultures activated with low doses of
antigen (data not shown), but the pattern shown is highly
consistent. Thus, we reliably observed that OVA/Kb binding
was ~5- to 10-fold lower on activated OT-I cells compared
with antibody-blocked naive cells with similar levels of avail-
able OT-I TCR (Fig. 2C). These data again suggest that
activation impairs ligand binding beyond levels expected
from TCR down-regulation, and that changes in TCR levels
alone do not account for the loss of multimer binding.
Role of CD8 in the activation-induced loss in
peptide/MHC binding
We next tried to determine the underlying mechanism for
this activation-induced phenomenon. Previous work has
demonstrated a critical role for CD8 in binding cognate
multimers on naive OT-I cells (23, 32). Subsequent work has
shown that CD8 binding to non-antigen Class I (i.e. non-
cognate binding) can be detected using peptide/MHC
multimers. This binding is considerably weaker on mature,
naive CD8+ T cells compared with immature CD4+8+
thymocytes (10, 11, 24, 25). However, we recently established
methods which enhance detection of non-cognate binding on
naive T cells (see experimental procedures). Using these
improved staining conditions, non-cognate multimer staining
of naive OT-I cells could be detected.
We activated naive OT-I cells as described above and
stained the cells with non-cognate (P815/Kb) multimers on
successive days. The binding of CD8 to Class I multimers
dropped to nearly undetectable levels within the first day after
activation, and this phenomenon persisted throughout the
time course (Fig. 3A). Importantly, this loss in non-cognate
multimer binding could not be attributed to changes in surface
levels of either CD8a or CD8b. Consistent with other reports
(3), CD8 expression remained relatively constant throughout
the activation (Fig. 3 and data not shown). This result implies
that the drop in Class I MHC multimer binding is a result of
changes in the ‘quality’ of the CD8 molecules, not the quantity
of its expression.
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We were also interested in determining how early this
phenomenon can be detected after activation. We observed
changes in non-cognate multimers at 8-h post-activation
(Fig. 3B). These data argue against a model in which the
loss in multimer avidity was due to changes in cell size since
cells at this time point have not begun blasting (data not
shown). We detected a slight drop in non-cognate multimer
binding when OT-I cells were cultured without antigen stimulus
at this time point, which may be attributable to a slight loss of
CD8b levels (Fig. 3B); however, the loss in binding due to
activation is much more pronounced. It is important to note
that loss of cognate binding is also severely impaired at 8 h of
activation, however TCR down-regulation is also quite marked
at this time point (data not shown).
Hence, these data suggested that T cell activation leads to
a profound, rapid and sustained loss in CD8–Class I binding.
Activation induces loss of TCR– and CD8–Class I binding by
2C CD8+ T cells
While the data above implicated changes in CD8 binding as
a basis for the loss of specific peptide/MHC binding by
activated OT-I cells, we wanted to determine whether CD8-
independent binding to the TCR was also influenced by
activation.
For this, we turned to the 2C TCR transgenic system. As
we and others have shown previously, 2C TCR binding to
the SIY/Kb ligand can be detected even when CD8 molecules
are absent or blocked (23, 32). Hence, to look at multimer
binding in the absence of CD8 co-receptor participation, we
stained resting and activated 2C cells with SIY/Kb multimers
in the presence of the blocking CT-CD8a antibody. This
antibody inhibits CD8-dependent multimer staining (23, 32).
Activated 2C CD8 T cells showed a decline in TCR binding to
Fig. 1. Binding to specific peptide/MHC ligands is impaired on activated CD8 Tcells, despite normal TCR levels. OT-I cells were stimulated in vitro
with 1 lM OVA. In (A) cells were assessed for binding to high-affinity (OVA/Kb) or low-affinity (G4/Kb) Class I MHC multimers over several days of
activation, compared with naive OT-I. Staining was performed using 2 lg ml1 of multimer in FACS buffer (for OVA/Kb) or 10 lg ml1 of multimer in
RP10 media (G4/Kb), to attain similar levels of overall multimer staining. OT-I TCR levels were measured with the B20.1 specific for the Va2 chain.
Representative histograms from days 1, 3 and 4 post-activation are shown. Median fluorescence intensities (MFIs) for activated cells are listed in
the upper left corner and naive MFIs on the upper right corner. In (B) unstimulated or day 1 activatedOT-I were stained with titered doses of OVA/Kb
multimers (in FACS buffer) or G4/Kb multimers (in RP10) at the doses indicated. Activation-induced loss of OT-I TCR expression was similar to that
shown in (A) (data not shown).
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SIY/Kb multimers in these assays (Fig. 4). The kinetics of
multimer loss correlated with the drop in TCR levels at days 1
and 2 of post-activation, but the magnitude of the loss in
surface TCR did not match that of the reduction in multimer
staining (Fig. 4). Furthermore, TCR levels were similar to those
on naive 2C cells at day 3 of activation, yet CD8-independent
multimer binding is still only 60% of naive, suggesting that
activation influenced the ability of the TCR to interact with its
ligand. We saw similar results using SIY/KbD227K multimers,
which bear a crippling mutation in the CD8-binding site (data
not shown). While we had hoped to analyze the CD8-negative
2C population in these experiments, these cells were poorly
stimulated and rapidly lost in our activation cultures, limiting
our ability to track their multimer-binding potential (data not
shown).
Wealso studied2Cbinding toSIY-A6/Kbmultimers. SIY-A6/Kb
was defined as an antagonist for 2C T cells (33), and is pre-
sumed to bind the 2C TCR with a lower affinity than SIY. Unlike
SIY/Kb, 2CstainingwithSIY-A6/Kbmultimers ishighlydependent
onCD8 (Fig. 4) (34). Similar to theOT-I system,cognatemultimer
binding to this low-affinity ligand was drastically impaired
following 2C activation, and this effect was maintained over
several days, even after TCR expression had returned to the
same levels as naive 2C cells (Fig. 4). As with OT-I cells, CD8ab
levels were not notably changed on activated 2C cells, yet non-
cognate binding by 2C T cells (to OVA/Kb multimers) was
drastically reduced (data not shown).
Hence, these data suggest that both CD8–Class I and TCR–
Class I interactions with specific peptide/MHC ligands are
compromised following T cell activation, but argue that CD8-
dependent multimer binding is much more severely impacted.
Activation-induced loss in multimer binding is partially
attributable to surface sialylation
Our laboratory and that of others have previously demon-
strated that cell-surface sialylation is inversely correlated with
non-cognate Class I multimer binding (10, 11). We examined
the effects of surface sialylation on non-cognate multimer
binding after activation using V. cholera neuraminidase,
a broad range sialidase which cleaves sialic acid from many
types of glycan adducts, including CD8 itself (13, 35). Hence,
we tested whether neuraminidase would also influence multi-
mer binding to activated CD8 T cells.
OT-I lymph node cells were activated with OVA in vitro for
60 h and stained with cognate and non-cognate multimers. As
expected, OT-I activation led to notable loss of OVA/Kb multimer
binding and profound decrease in binding of G4/Kb (low-TCR
affinity ligand) and P815/Kb (non-cognate ligand) (Fig. 5).
Fig. 2. Mimicking TCR down-regulation by antibody blockade on naive OT-I cells reveals an additional activation-induced effect that impacts
peptide/MHCmultimer binding. (A) Naive OT-I Tcells were coated with increasing doses of the blocking monoclonal anti-Va2 antibody, B20.1, and
then stained with OVA/Kb multimer (2 lg ml1 in FACS buffer) to assess antigen binding or with a PE-labeled B20.1 to measure remaining unbound
levels of surface TCR. (B and C) OT-I cells were activated with 1 lM and 1 nMOVA, respectively. Relative median fluorescence intensities (MFIs) of
bound OVA/Kb multimers or TCR levels were plotted on line graphs in the top panels. The bar graphs in the bottom panels compare OVA/Kb
staining between cells that show an equivalent loss in TCR levels due to activation (day 1) or surface blockade with B20.1 described in (A).
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In parallel, we treated both naive and the activated OT-I
cells with neuraminidase, as described previously (10).
Intriguingly, both cognate and non-cognate multimer binding
were substantially enhanced by neuraminidase treatment of
the activated OT-I cells (Fig. 5). Binding of OVA/Kb and, to an
even greater extent, G4/Kb multimers was enhanced by
desialylation of activated OT-I cells, and binding approached
the levels seen on desialylated naive OT-I cells. Even after
neuraminidase treatment, though, the cognate multimer
binding on activated OT-I cells was slightly lower than that
on naive cells, most likely due to the fact that TCR levels
had not completely recovered to naive levels (Fig. 5).
The effect on non-cognate binding was even more dra-
matic. As expected, activated OT-I cells showed inefficient
non-cognate multimer binding compared with naive OT-I cells,
yet neuraminidase treatment disproportionately enhanced
non-cognate multimer binding to the activated T cells, such
that desialylated activated and naive OT-I cells now had
similar staining intensities (Fig. 5).
In additional experiments, we found that this enhancing
effect of desialylation on non-cognate CD8 binding also ap-
plied to cells at days 1 and 2 of activation (Fig. 6). As we have
previously shown, binding of both cognate and non-cognate
Class I MHC ligands can be enhanced by the anti-CD8a
antibody 53-6.7 (10, 23), which may be due to the stabil-
ization of a Class I ‘receptive’ conformation of CD8 (36).
When included in staining assays of activated OT-I cells, 53-
6.7 increased non-cognate multimer binding, but still did not
fully compensate for the loss of non-cognate multimer bind-
ing seen with OT-I activation (Fig. 6). Interestingly, however,
Fig. 3. Down-regulation of CD8 avidity for non-cognate Class I MHC on activated OT-I is rapid and sustained. (A) OT-I cells were activated in vitro
with 10 nMOVA, and non-cognate P815/Kb multimer binding and CD8 levels weremeasured daily from days 1 to 5 post-activation. Themonoclonal
anti-CD8a antibody, CT-CD8a, was used to block non-cognate binding on naive cells and shown as a baseline for comparison in the top row.
(B) OT-I cells were activated as described above and assessed for non-cognate binding and CD8 levels 8-h post-stimulus. The staining for cells
cultured ex vivo for 8 h without antigen stimulation is also shown. In all cases, staining used 50 lg ml1 P815/Kb multimer in RP10 at 4C.
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a combination of neuraminidase treatment and staining with
the 53-6.7 antibody restored non-cognate multimer staining
on activated OT-I cells to the levels seen on naive OT-I cells
(Fig. 6). The binding of the non-cognate multimers (with or
without neuraminidase treatment) was completely blocked by
CT-CD8a (Fig. 6) which we previously showed inhibits CD8–
Class I multimer binding (10, 23), strongly suggesting that all
of the binding observed involves CD8 directly.
As reported previously, staining with PNA (a lectin which
binds unsialylated core-1 O-glycans) increases on activated
CD8 T cells, including OT-I (37, 38). Naive T cells are heavily
sialylated at core-1 O-glycans residues [due to the action of
ST3Gal-I (16, 39)], and hence staining by PNA is low on naive
cells (Fig. 6) (10, 11, 37, 38). Under our stimulation conditions,
at 24 h of activation, PNA binding is only modestly enhanced
(Fig. 6B) compared with naive cells, but PNA staining
increases markedly by 48–72 h (Fig. 6B) as shown previously
for OT-I cells (37). Hence, despite the fact that the cells
are becoming desialylated on some O-linked residues,
neuraminidase still has the capacity to enhance non-cognate
multimer binding at these time points.
Overall then, these results suggest that changed sialylation
may account for at least some of the defective non-cognate
and cognate multimer binding which accompanies T cell
stimulation. Moreover, these data suggest that neither CD8 nor
TCR molecules on activated T cells are irreversibly comprom-
ised in their capacity to bind Class I ligands.
Discussion
MHC/peptide multimers have revolutionized the capacity to
identify T lymphocytes participating in an immune response,
permitting enumeration of antigen-specific T cells without
requiring them to survive in tissue culture or respond to antigen
in vitro. However, as we describe in this report, peptide/MHC
multimer staining is not simply a reflection of TCR/CD8 surface
expression, but rather is strongly influenced by the activation
state of the T cell. These changes have a profound practical
significance, in that multimer binding may be a misleading
method of detecting antigen-specific T cells shortly after their
stimulation in a normal immune response—indeed our data
would suggest that highly CD8-dependent Tcells, and/or those
responding with low affinity for the peptide/MHC ligand, may be
undetectable using standard multimer binding assays. Similar
conclusions were reached by Braciale and colleagues in an
intriguing report, published during review of this manuscript,
which showed loss of cognate Kd multimer binding on CD8
Tcells responding to influenza in vivo, despite high expression
levels of TCRandCD8ab (40). Interestingly, the oppositemaybe
true of staining antigen-specific CD4 T cells since data from
Fig. 4. Activated 2C CD8+ Tcells show loss in CD8-dependent and -independent peptide/MHCmultimer binding. Bulk lymph node 2C cells were
activated in vitro with 1 lM of SIY peptide and assessed daily from days 1 to 4 for binding to multimers and TCR levels. The top row shows binding
to high-affinity SIY/Kb multimers in the presence of the blocking anti-CD8a antibody, CT-CD8a, to assess TCR avidity alone in the absence of CD8
co-receptor contribution. The middle row shows binding to low-affinity SIY-A6/Kb multimers with or without CT-CD8a. The bottom panels show TCR
levels using a Vb8-specific antibody. All multimers were used at a concentration of 10 lg ml1.
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Cameronet al. (41) indicated that efficientClass IIMHCmultimer
staining of CD4 T cells requires activation-induced multimer
internalization.
We observe that T cell activation leads to dramatic and
rapid loss in specific peptide/MHC multimer binding. While
some loss in cognate multimer binding was predicted due to
transient TCR down-regulation with activation, the loss of
multimer staining does not correlate with TCR down-regulation
either in its magnitude or duration. Thus we found that, for both
the OT-I and 2C systems, defective cognate multimer binding
was impaired on activated T cells even when TCR levels had
recovered to the levels on naive cells. Furthermore, anti-TCR
antibody treatment of naive T cells could block the TCR down
to levels seen on activated Tcells, but did not reduce cognate
multimer binding to the same extent (Fig. 2). Hence, our data
suggest that loss of multimer binding occurs not only in
‘unusual’ Tcell responses [such as those directed against sub-
dominant epitopes or during chronic Tcell responses (18–22)]
but this same phenomenon occurs in following conventional,
acute T cell activation, a conclusion reinforced by the recent
report from Drake et al. (40). Our report further suggests that
changes in CD8–Class I binding, in part mediated by altered
cell-surface sialylation, contribute to such changes in TCR/
CD8–Class I MHC binding.
Numerous reports have shown that peptide/MHC Class I
multimer binding requires coordinate recognition by both TCR
and CD8 (23). Thus, it was important to determine whether
loss of cognate multimer staining was due to impairment in
TCR and/or CD8 engagement. Our data suggest that CD8
binding is profoundly impaired following Tcell activation. TCR-
independent (non-cognate) CD8 binding was virtually abol-
ished, and CD8-dependent TCR interactions, especially with
low-affinity TCR ligands, were also severely compromised.
Analysis of CD8-independent multimer binding in the 2C
system argued that TCR binding per se was less dramatically
influenced, although some impairment was noted.
We had initially expected that naive T cell activation would
increase CD8 non-cognate binding, based on the work
performed with CTL clones which showed poor CD8-mediated
adhesion to non-cognate Class I until the cells were activated
through the TCR (8, 9, 42). Our data indicate that stimulation of
naive Tcells leads to the opposite pattern, in which CD8–Class
I binding is diminished. Interestingly, preliminary data suggest
that, consistent with published reports using Class I adhesion
assays (8, 9, 42), TCR stimulation of CTL clones leads to
increased levels of non-cognate multimer binding (C.K. and
S.C.J., unpublished results). Such data would argue that
the regulation of CD8–Class I binding on naive versus
differentiated CD8 T cells is quite different, a possibility which
we are currently exploring.
Loss of multimer binding did not correlate solely with
receptor expression levels, suggesting a qualitative effect
on CD8/TCR capacity to bind multimers. Drake et al. (40)
showed that activation induced changes in cell-surface
distribution of TCR molecules. This model may correlate with
the effect of neuraminidase which we report here since
previous reports have argued that desialylation can influence
the ability of the TCR to cluster and engage peptide/MHC
ligands (43). The effect of desialylation on activated T cells
was unexpected, since effector T cells are known to have
already decreased in cell-surface sialylation (12, 15, 16),
including changes in sialylation of CD8 itself following T cell
activation (13, 38). One likely explanation for this evident
discrepancy is the specificity of sialylation. There are more
than a dozen murine sialyltransfersases, which differ with
respect to the anomeric linkage of the sialic acid adduct
as well as substrate preferences (44). Indeed, the sialyltrans-
ferase ST6GalNAc IV has been shown to be induced by
activation of CD8 T cells, with similar kinetics to the effects
documented here (45), and this enzyme represents a good
candidate for control of the phenotype reported here. A more
complex issue will be to determine whether changes in CD8
Fig. 5. Neuraminidase treatment restores both cognate and non-cognatemultimer binding on activatedOT-I. OT-I lymph node cells were activated
in vitro for 60 h and stained with high-affinity cognate (2 lg ml1 OVA/Kb), low-affinity cognate (10 lg ml1 G4/Kb), or non-cognate (50 lg ml1
P815/Kb) multimers. Histograms compare levels between naive and activated OT-I CD8+ Tcells. Top and lower rows show staining on cells before
and after neuraminidase treatment, respectively. The extent of TCR down-regulation is also shown, by staining for Va2 (right hand panel).
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sialylation itself plays the key role, or whether changes in other
(more prominently glycosylated) T cell surface molecules
influence the access of CD8 with its ligand, a model which has
been proposed earlier (46).
Other changes might also regulate CD8 (and/or TCR) ligand
binding by activated Tcells. An interesting mechanism is sug-
gested by the recent report which proposed the production
of CD8aa homodimers on activated CD8 T cells (47). CD8aa
binds well to the non-classical Class I molecule TL, but
poorly to classical Class I MHC molecules (11, 24, 48),
hence such a change might contribute to the loss of Kb
multimer binding studied here. However, the report from
Madakamutil et al., and our own unpublished studies using
TL multimers (kindly provided by H. Cheroutre) suggest that
up-regulation of CD8aa expression is detected at 48 h but
not at 24 h (data not shown), whereas we see profound
impairment of cognate and non-cognate binding by day 1
of activation (Figs 3, 5 and 6). Thus, although appearance
of the TL-binding form of CD8 may play a role at later
stages of activation, this effect appears not to account for
the early loss in classical Class I multimer binding we report
here.
But what might be the physiological role for this change
in Class I MHC binding? Loss of binding to specific peptide/
MHC ligands might seem counterintuitive, given the functional
sensitivity of CTLs. Indeed, previous data from Schneck and
colleagues suggested that effector CTLs were superior to
naive cells in binding bivalent cognate peptide/MHC ligands
at low density (7). This may relate simply to the valency of the
peptide/MHC ligands used in these studies. It is interesting
to note however, that Fahmy et al. used 2C Tcells at>d4 post-
activation, and exclusively studied binding of high-affinity
cognate ligands. In our hands, such binding is largely CD8
independent and is mostly restored by that time point (Fig. 4).
Thus, although we have been unable to observe enhanced
multimer binding on activated T cells, such effects may be
more subtle than the large-scale loss in multimer binding we
observe at earlier activation time points. Furthermore, we ob-
serve a greater impact of activation on binding to lower affinity
cognate ligands. For both the OT-I system (G4/Kb binding,
Fig. 6. Staining with the enhancing CD8 antibody 53-6.7 together with desialylation restores non-cognate CD8 binding on activatedOT-I. (A) Naive
and activated (days 1 and 2) OT-I cells were stained for non-cognate multimer binding similar to Fig. 5. The cells were untreated, neuraminidase
treated and/or stained in the presence of the CD8a antibody 53-6.7 as indicated, and multimer (VP10/Kb) staining was determined (open
histogram). In addition, the untreated and neuraminidase-treated groups were stained with VP10/Kb multimer in the presence of CT-CD8a, which
blocks CD8–Class I interactions (gray histograms), to demonstrate that neuraminidase treatment does not lead to non-specific multimer binding.
Lines are shown at the mean fluorescence of the multimer staining on the naive population, to help align multimer binding on the activated cells.
Multimers were used at 30 lg ml1 (for staining with CT-CD8a or without CD8 antibodies) or 10 lg ml1 (for staining in the presence of 53-6.7).
(B) PNA staining of OT-I cells after activation. Naive OT-I (shaded) and activatedOT-I at days 1 (solid line), 2 (cross-hatched) or 3 (broken line) were
stained with PNA–FITC.
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Fig. 1) and 2C (SIY-A6/Kb binding, Fig. 4), activated T cells
suffered a profound and sustained loss in binding to these
types of ligands. Hence, these data do not necessarily
disagree with the report by Fahmy et al., but suggest that
enhanced peptide/MHC recognition by effector T cells is
preceded by stage of reduced sensitivity.
The changes in peptide/MHC ligand binding which we
observe would be expected to have functional consequences.
Indeed, recent data from Braciale’s group suggest that
tetramerlow cells are altered in their ability to respond to TCR
engagement, showing depressed calcium flux, IFN-c synthe-
sis and degranulation (40). Our data on the decreased ability
of activated T cells to engage low-affinity peptide/MHC li-
gands suggests additional consequences. The first is that
activated Tcells with the lowest affinity for a stimulatory foreign
peptide/MHC ligand will disproportionately lose sensitivity
to it. These clones would therefore fail to receive further stimu-
lation by the antigen and may be outcompeted by more ‘fit’
clones (i.e. in this context, T cells bearing TCRs with higher
affinity for the foreign peptide/MHC ligand). Furthermore, loss
of binding to low-affinity peptide/MHC ligands may prevent
recognition of self-peptide/MHC ligands. Numerous experi-
ments suggest that naive T cells engage self-peptide–MHC
complexes, resulting in basal TCR signaling, which may
influence T cell homeostasis (49–51). However, were these
interactions to be maintained in the effector T cell population,
there is grave potential for autoaggressive responses. Hence,
activation-induced desensitization to these (low affinity) self-
ligands may be beneficial for the host.
Alternatively, it has long been appreciated that repeated
TCR stimulation of T cells can lead to activation-induced cell
death, hence the loss of peptide/MHC ligand binding we
report may enhance effector survival. A distinct element in
this argument is suggested by data from Potter’s group,
showing immature thymocyte sensitivity to apoptosis induced
by non-cognate CD8 interactions (52). It is possible that
loss of non-cognate binding protects highly vulnerable acti-
vated CD8 T cells from apoptosis induced in the same way,
a possibility we are currently exploring. Clearly, further
experiments will be needed to elucidate the consequences
of decreased peptide–MHC interactions on activated CD8
T cells.
In summary, our data suggest that CD8 T cells pass
through a stage of depressed CD8/TCR binding following
activation, which may influence the fate of the activated Tcells
and selection for the most robust responder cells. It is
interesting to note that TCR engagement during positive
selection in the thymus also leads to decreased TCR/CD8
binding and sensitivity, and that this process is also regulated
by changes in sialylation. Such data suggest that T cells
have an unexpectedly large dynamic range in the ability of
their receptors to engage peptide/MHC receptors during
differentiation.
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